Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis.

The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for moderate to severe psoriasis

Sun Pharma acquired the rights of the molecule from MSD, known as Merck in the US and Canada, for $80 million in 2014 to grow its position in dermatology. Last year, Sun Pharma sold the rights to this drug to Spanish company Almirall for the European market.  Almirall will take charge of clinical studies for Europe.

The FDA accepted the Biologics License Application (BLA) for tildrakizumab in late May 2017. The BLA filing was submitted by Merck & Co., Inc., Kenilworth, NJ, USA.